Discharge Standards and Monitoring Plan for Patients with COVID-19
Posted: Sun Feb 02, 2025 8:45 am
COVID-19 Nucleic Acid Test: The patient should have tested negative on at least two consecutive nucleic acid tests more than 24 hours apart. Given the increased incidence of COVID-19 test result reversal from negative to positive after treatment, it is recommended to revise the standard to three consecutive negative results. Ideally, all body fluid samples should be negative, including blood, sputum, nasopharynx, bronchoalveolar lavage, urine, and stool. Given the complexity of the procedure, however, at least sputum and bronchoalveolar lavage samples should be negative.
Infection status assessment: During long-term hospitalization, some COVID-19 patients may have multiple bacterial infections, and therefore a complete medical evaluation is recommended to assess the infection control situation, especially if there is a multidrug-resistant bacterial infection. In addition, post-procedural antibacterial treatment plans should be developed to assess the risk of developing postoperative infections.
Preoperative medical assessment process for lung transplantation in COVID-19 patients: treatment plan proposed by the ICU team - interdisciplinary discussion - comprehensive medical assessment - analysis japan number data and treatment of relative contraindications - prehabilitation before lung transplantation.
2 Contraindications
Please refer to the 2014 ISHLT consensus statement: Consensus document on selection of candidates for lung transplantation issued by the International Society for Heart and Lung Transplantation (updated 2014).
XVII.
1 Discharge standards
Body temperature remains normal for at least 3 days (ear temperature below 37.5 °C);
Respiratory symptoms improve significantly;
Nucleic acid is tested negative for the respiratory tract pathogen on two consecutive occasions (sampling interval >24 hours); nucleic acid is tested on stool samples, if possible, at the same time;
Lung imaging shows obvious improvement in lesions;
There are no concomitant diseases or complications requiring hospitalization;
SpO2> 93% without oxygen supplementation;
The discharge was approved by a multidisciplinary medical team.
2 Drug treatment after discharge
Infection status assessment: During long-term hospitalization, some COVID-19 patients may have multiple bacterial infections, and therefore a complete medical evaluation is recommended to assess the infection control situation, especially if there is a multidrug-resistant bacterial infection. In addition, post-procedural antibacterial treatment plans should be developed to assess the risk of developing postoperative infections.
Preoperative medical assessment process for lung transplantation in COVID-19 patients: treatment plan proposed by the ICU team - interdisciplinary discussion - comprehensive medical assessment - analysis japan number data and treatment of relative contraindications - prehabilitation before lung transplantation.
2 Contraindications
Please refer to the 2014 ISHLT consensus statement: Consensus document on selection of candidates for lung transplantation issued by the International Society for Heart and Lung Transplantation (updated 2014).
XVII.
1 Discharge standards
Body temperature remains normal for at least 3 days (ear temperature below 37.5 °C);
Respiratory symptoms improve significantly;
Nucleic acid is tested negative for the respiratory tract pathogen on two consecutive occasions (sampling interval >24 hours); nucleic acid is tested on stool samples, if possible, at the same time;
Lung imaging shows obvious improvement in lesions;
There are no concomitant diseases or complications requiring hospitalization;
SpO2> 93% without oxygen supplementation;
The discharge was approved by a multidisciplinary medical team.
2 Drug treatment after discharge